ArticleBreast cancer research and treatment2025
SOD2 expression in patients with triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and prognosis.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Size-Dependent Differences in the Effects of Low-Dose Selenium Nanoparticles on Chronic Thioacetamide Toxicosis Accompanying HCC Progression in Mice.Biological trace element research · 2026Article
- Integrated Assessment of HIF-1α and SOD2 Expression and Their Prognostic Implications in Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- JAB1/CRL4B complex represses PPARG/ACSL5 expression to promote breast tumorigenesis.Cell death and differentiation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeSuperoxide dismutase 2 (SOD2), an antioxidant enzyme, plays a pivotal role in carcinogenesis and immune regulation. In this study, we investigated the expression and implications of superoxide dismutase (SOD2) in triple-negative breast cancer (TNBC), an aggressive subtype with varying immune profiles and clinical outcomes.
methodsMultiple TNBC cohorts were analyzed with various methodologies including immunohistochemistry (IHC), proteomics, and RNA expressions. Immunostaining of SOD2 with tissue microarrays from 229 surgical samples and 144 pre-neoadjuvant chemotherapy biopsy samples were performed. Four hundred three formalin-fixed and paraffin-embedded samples underwent deparaffinization for protein extraction and three hundred thirty-six samples remained after quality control. Ninety-one TNBC samples from The Cancer Genome Atlas data and five hundred thirty-four TNBC samples from public database were also analyzed.
resultsWe identified positive correlations between SOD2 expression and immune-related genes, as well as tumor-infiltrating lymphocytes (TILs) levels, while observing negative associations with fibrosis-related pathways. Immunohistochemical analysis further supported the positive correlation between SOD2 and immune response. Furthermore, elevated SOD2 expression predicted favorable survival outcomes in patients with TNBC. Notably, analysis of single-cell RNA-seq data revealed increased SOD2 expression in cancer-associated fibroblasts associated with higher TILs levels, enhanced inflammatory signaling, and reduced fibrogenesis.
conclusionHigh SOD2 expression in TNBC is associated with improved outcomes and heightened immune responses, underscoring its potential as a modulator of the tumor microenvironment.
Indexed as
Identifiers
40634732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.